Alphabiomics

Executive Summary

Alphabiomics is a UK-based biotechnology company specializing in gut health diagnostics through its AI-powered AlphaGutScan platform. Founded in 2013, the company has developed a science-based test that analyzes individual microbiomes and translates complex microbial data into personalized health recommendations. As a private diagnostics company, Alphabiomics aims to address the growing consumer demand for at-home health testing and precision nutrition. The company operates in the competitive microbiome diagnostics space, but its focus on actionable insights and AI integration differentiates it. With no disclosed funding or revenue details, Alphabiomics appears to be in an early commercial stage, likely seeking strategic partnerships or additional capital to scale. Its profile has low visibility, suggesting limited market traction to date, but the gut health market is expanding rapidly, presenting opportunities for growth if the company can execute effectively.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a major health or nutrition brand40% success
• Q4 2026New product launch or expansion into international markets50% success
• Q3 2026Series A funding round or government grant announcement35% success